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Macrophages play central roles in the development of atherosclerosis through modulation of cholesterol 
homeostasis, the immune-inflammatory response, and plaque 
cellularity.1 Macrophage activation and survival are crucial 
determinants of atherosclerotic lesion development.2 In addi-
tion, macrophages contribute to the integration of immune 
and metabolic responses, and their dysfunction contributes to 
chronic metabolic disorders, such as obesity, type 2 diabetes 
mellitus, and cardiovascular disease.3
The c-Jun NH
2
-terminal kinases (JNK) belong to the stress-
activated protein kinase family, which are activated by a vari-
ety of environmental (radiation, osmotic, and redox stress) and 
metabolic stresses, cytokines, and growth factors.4,5 JNK plays 
an important role in inflammatory signaling, and its activation 
is crucial for programmed cell death.6 In mammals, the JNK 
protein kinases are encoded by 3 genes: Jnk1, Jnk2 and Jnk3, 
which transcribe several alternatively spliced isoforms.7 Jnk1 
and Jnk2 genes are expressed ubiquitously, whereas the Jnk3 
gene is restricted to the brain, cardiac smooth muscle, pan-
creatic islets, and testis.4 The targeted disruption of the Jnk1 
or Jnk2 genes revealed that they compensate for each other’s 
activity and are functionally redundant,8 but each isoform also 
exhibits distinct roles.9 For example, activation of CD8+ T cells 
is impaired in Jnk1 knockout mice but enhanced in Jnk2 null 
mice.10 Loss of Jnk1, but not Jnk2, suppresses obesity and 
improves insulin sensitivity in mice.11 JNK1, but not JNK2, 
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Objective—The c-Jun NH
2
-terminal kinases (JNK) are regulated by a wide variety of cellular stresses and have been 
implicated in apoptotic signaling. Macrophages express 2 JNK isoforms, JNK1 and JNK2, which may have different 
effects on cell survival and atherosclerosis.
Approach and Results—To dissect the effect of macrophage JNK1 and JNK2 on early atherosclerosis, Ldlr−/− mice were 
reconstituted with wild-type, Jnk1−/−, and Jnk2−/− hematopoietic cells and fed a high cholesterol diet. Jnk1−/−→Ldlr−/− mice 
have larger atherosclerotic lesions with more macrophages and fewer apoptotic cells than mice transplanted with wild-
type or Jnk2−/− cells. Moreover, genetic ablation of JNK to a single allele (Jnk1+/−/Jnk2−/− or Jnk1−/−/Jnk2+/−) in marrow 
of Ldlr−/− recipients further increased atherosclerosis compared with Jnk1−/−→Ldlr−/− and wild-type→Ldlr−/− mice. In 
mouse macrophages, anisomycin-mediated JNK signaling antagonized Akt activity, and loss of Jnk1 gene obliterated 
this effect. Similarly, pharmacological inhibition of JNK1, but not JNK2, markedly reduced the antagonizing effect of 
JNK on Akt activity. Prolonged JNK signaling in the setting of endoplasmic reticulum stress gradually extinguished Akt 
and Bad activity in wild-type cells with markedly less effects in Jnk1−/− macrophages, which were also more resistant to 
apoptosis. Consequently, anisomycin increased and JNK1 inhibitors suppressed endoplasmic reticulum stress–mediated 
apoptosis in macrophages. We also found that genetic and pharmacological inhibition of phosphatase and tensin homolog 
abolished the JNK-mediated effects on Akt activity, indicating that phosphatase and tensin homolog mediates crosstalk 
between these pathways.
Conclusions—Loss of Jnk1, but not Jnk2, in macrophages protects them from apoptosis, increasing cell survival, and this 
accelerates early atherosclerosis.  (Arterioscler Thromb Vasc Biol. 2016;36:1122-1131. DOI: 10.1161/ATVBAHA. 
116.307580.)
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activation plays an important role in the pathogenesis of insulin 
resistance.12–14 Examination of cell types involved in metabolic 
functions of JNK illustrated contributions from many stromal 
cell types, including neuronal cells, adipocytes, and hepato-
cytes.14,15 Several studies also demonstrated the involvement 
of macrophage JNK activity at varying degrees in obesity and 
insulin resistance.8,12,14 Ricci et al16 have shown that apoE null 
(apoE−/−) mice lacking Jnk2 (apoE−/−/Jnk2−/− mice) develop 
less atherosclerosis than apoE−/− or apoE−/−/Jnk1−/− mice. The 
effect of loss of Jnk2 on atherosclerosis was attributed to 
reduced scavenger receptor A expression and foam cell forma-
tion by macrophages.16 However, the role of macrophage JNK 
isoforms on apoptosis in the setting of atherosclerosis was not 
assessed, and additional studies are needed to evaluate the role 
of individual macrophage JNK isoforms in atherogenesis.5
JNK signaling has been implicated in apoptosis in response 
to a variety of stress stimuli.4,6 Although both JNK1 and JNK2 
are involved in apoptotic signaling, only JNK1 is considered 
to be essential for apoptosis.17 Murine embryonic fibroblasts 
lacking Jnk1, but not Jnk2, have reduced c-Jun phosphoryla-
tion and ultraviolet-induced cell death.18 Loss of both Jnk1 and 
Jnk2 in murine embryonic fibroblasts produces a defect in death 
signaling and protects them from apoptosis.19 Interestingly, the 
role of JNK in apoptosis depends on the activity of other cel-
lular signaling pathways, including the prosurvival phosphati-
dylinositol-3-kinase (PI3K/Akt).20,21 Aikin et al22 were the first 
to report cross talk between the PI3K/Akt and JNK pathways 
that protects islet cells from apoptosis. In addition, Sunayama 
et al23 have shown that JNK signaling antagonizes Akt activity 
in mammalian cells making them more susceptible to apop-
tosis. Similarly, JNK inhibition significantly suppresses pan-
creatic β-cell death24 and decreases macrophage apoptosis.25 
Interestingly, phosphatase and tensin homolog (PTEN) may 
play a key role in the cross talk between the PI3K/Akt and 
JNK pathways, and PTEN deficiency impairs negative feed-
back regulation of PI3K in cancer cells.26 However, the precise 
role of JNK signaling in apoptosis depends on the cell type and 
the nature of the death stimulus.6,17 It is unclear whether JNK 
antagonizes Akt activity in mouse macrophages or whether 
this cross talk is mediated via PTEN with consequent suppres-
sion of cell survival that affects atherogenesis.
Here, we used genetic loss-of-function and pharmacologi-
cal inhibition approaches to investigate the effect of JNK1 
and JNK2 on Akt signaling in mouse macrophages and ath-
erogenesis. Our data demonstrate the critical role of JNK1 
signaling in macrophage apoptosis and development of early 
atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
JNK Deficiency in Hematopoietic Cells Increases 
Early-Stage Atherosclerotic Lesions
To examine the effect of hematopoietic cell Jnk1 and Jnk2 
deficiency on atherosclerosis, 22-week-old male Ldlr−/− mice 
were lethally irradiated and transplanted with male wild-type 
(WT; n=14), Jnk1−/− (n=11), or Jnk2−/− (n=13) bone marrow. 
After 4 weeks on a normal chow diet, mice were fed with the 
Western diet for another 8 weeks. No significant differences 
between the recipient groups were detected in body weight, 
serum total cholesterol, and triglyceride levels on the chow and 
the Western diets (Table, A). Size exclusion chromatography 
of serum revealed an accumulation of cholesterol in very low-
density lipoprotein, low-density lipoprotein, and intermedi-
ate-density lipoproteins fractions in Ldlr−−/− recipients with no 
differences between control and experimental groups in either 
experiment (data not shown). Mice reconstituted with WT, 
Jnk1−/−, and Jnk2−/− marrow had similar levels of blood glu-
cose (133.7±5.3, 139±6.8, and 137±6.7 mg/dL, respectively), 
Nonstandard Abbreviations and Acronyms
ER endoplasmic reticulum
JNK c-Jun NH2-terminal kinases
PTEN phosphatase and tensin homolog
WT wild-type
Table.  BW, TC, and TG Levels in Male Ldlr−/− Mice Reconstituted With WT, Jnk1−/−, Jnk2−/−, Jnk1+/−/Jnk2−/−, and 
Jnk1−/−/Jnk2+/− Hematopoietic Cells on Chow and High-Fat Diets
Type of Bone Marrow 
Reconstituted
Chow Diet High-Fat Diet
BW, g TC, mg/dL TG, mg/dL BW, g TC, mg/dL TG, mg/dL
A
  WT (n=14) 29.3±0.6 242±11 125±4 32.3±0.7 1063±49 453±40
  Jnk1−/− (n=11) 27.8±0.5 245±16 137±5 29.8±0.9 1030±74 472±79
  Jnk2−/− (n=13); P values 28.0±0.8; 0.21 213±13; 0.20 135±6; 0.15 29.9±0.4; 0.75 1073±84; 0.44 465±59; 0.90
B
  WT (n=10) 28.0±0.7 208±4 116±6 30.8±1.2 974±98 322±21
  Jnk1−/− (n=10) 26.9±0.6 216±8 121±5 30.3±2.2 982±62 362±39
  Jnk1+/−/2−/−(n=13) 27.3±0.9 218±9 118±3 29.7±1.1 955±52 334±13
  Jnk1−/−/2+/−(n=12); P values 27.2±0.8; 0.66 213±5; 0.75 121±5; 0.12 29.3±0.7; 0.33 966±48; 0.99 345±24; 0.72
Values are in mg/dL (mean±SEM). The number of recipient mice in each group is indicated by n. The differences are not statistically significant 
between the groups by 1-way ANOVA. BW indicates body weight; TC, total serum cholesterol; TG, triglyceride; and WT, wild-type.
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erythrocytes (9.7±0.8, 9.9±1.1, and 9.7±0.9×106/μL), plate-
lets (649±66, 679±73, and 613±61×103/μL), and white blood 
cells (7.8±06, 9.1±0.7, and 7.5±0.45×106/mL). In contrast, the 
extent of atherosclerotic lesions in aortic sinus of the Jnk1−/−→
Ldlr−/− mice was markedly increased (Figure 1A and 1B) com-
pared with mice reconstituted with WT or Jnk2−/− marrow cells 
(Figure 1B; 241.6±38.1 versus 110.8±13.4 and 95.8±17.6×103 
μm2, respectively). Similarly, Jnk1−/−→Ldlr−/− mice had sig-
nificantly increased size of atherosclerotic lesions in the distal 
aorta compared with WT→ Ldlr−/− and Jnk2−/−→ Ldlr−/− mice 
(Figure 1C and 1D; 0.67%±0.22% versus 0.31%±0.10% and 
0.24%±0.07%, respectively).
Next, examination of the cellular composition of ath-
erosclerotic lesions in the aortic sinus of recipients showed 
that the proportion of smooth muscle, T, and B cells in ath-
erosclerotic lesions did not differ significantly between the 3 
groups (data not shown). The lesions predominantly consisted 
of macrophage-derived foam cells, and Jnk1−/−→Ldlr−/− mice 
had significantly bigger lesion area stained with antibody 
to MOMA-2 versus WT→Ldlr−/− and Jnk2−/−→Ldlr−/− mice 
(Figure 1A; 167.1±29.4 versus 82.4±10.3 and 76.4±4.6×103 
μm2, respectively). The analysis of serial aortic sections 
stained with MOMA-2 and terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick-end labeling (TUNEL) revealed 
that Jnk1−/−→Ldlr−/− mice contained significantly fewer num-
bers of apoptotic cells in macrophage-rich areas of lesions 
than WT→Ldlr−/− and Jnk2−/−→Ldlr−/− mice (Figure 1E and 
1F). Double staining of macrophages with MOMA-2 and 
cell nuclei with DAPI revealed increased (153%) numbers of 
nuclei per macrophage lesion area in Jnk1−/−→Ldlr−/− mice 
compared with lesions of WT→Ldlr−/− and Jnk2−/−→Ldlr−/− 
mice (Figure 1G). Together, the data indicate that the lack of 
Jnk1 in hematopoietic cells increases the burden of early ath-
erosclerotic lesions in the absence of changes in plasma lipid 
or glucose levels. The dramatic increase of macrophage num-
bers together with reduced apoptosis in atherosclerotic lesions 
of Jnk1−/−→Ldlr−/− mice also suggested changes in viability of 
JNK1−/−macrophages in vivo.
Figure 1. Loss of Jnk1 in hematopoietic 
cells increases atherosclerosis. A and C, 
Detection of atherosclerotic lesions in the 
aortic sinus and aortas pinned out en face 
in wild-type (WT)→Ldlr−/−, Jnk1−/−→Ldlr−/−, 
and Jnk2−/−→Ldlr−/− mice. Serial sections 
of the aortic sinus were stained with Oil 
Red O to detect neutral lipids or with the 
MOMA-2 antibody followed by biotinylated 
goat antirat IgG as the secondary antibody, 
avidin–biotin complex labeled with alkaline 
phosphatase, and Fast Red TR/naphthol 
AS-NX substrate to reveal macrophages. 
Aortas were pinned out and stained with 
Sudan IV. Scale bar, 200 μm; a pin size, 10 
μm. B and D, The extent of atherosclerotic 
lesions in the proximal and distal aorta 
of Ldlr−/− mice reconstituted with WT (◼), 
Jnk1−/− (□), or Jnk2−/− (◼) bone marrow. Note: 
atherosclerotic lesions are bigger in Jnk1−/−
→Ldlr−/− than in WT→Ldlr−/− and Jnk2−/−→L
dlr−/− mice. Graphs represent atherosclerotic 
lesion area (mean±SEM) of the recipient 
Ldlr−/− mice (*P<0.05 compared with control 
group, WT→Ldlr−/− mice, by Kruskal–Wallis 
1-way ANOVA on ranks, Dunn method). 
E, Detection of macrophages by staining 
with anti–MOMA-2 antibodies and apop-
totic cells by terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end label-
ing (TUNEL) in serial sections of the aortic 
sinus. Scale bar, 50 μm. F and G, Percent of 
TUNEL+ cells (F) and DAPI-stained nucleus 
numbers in MOMA-2+ area (G) in athero-
sclerotic lesions of WT→Ldlr−/−, Jnk1−/−→
Ldlr−/−, and Jnk2−/−→Ldlr−/− mice (*P<0.05 
compared with the control group by 1-way 
ANOVA on ranks).
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Genetic Ablation to a Single JNK Allele 
Further Increases Atherosclerosis
Peritoneal macrophages isolated from Jnk1−/−→Ldlr−/− and Jnk
2−/−→Ldlr−/− mice exhibited a significant decrease in JNK pro-
tein content compared with WT cells (Figure 2A; 0.49±0.03 
and 0.54±0.03 versus 1.0±0.01; P<0.05 by 1-way ANOVA) 
and JNK kinase activity (Figure I in the online-only Data 
Supplement). They also had minimal residual expression of the 
knocked out isoform with compensatory increased expression 
of the other isoform (Figure 2B), indicating that maintaining 
total JNK activity is a vital for macrophages. Hence, to exam-
ine the effect of further genetic suppression of JNK signal-
ing on atherosclerosis, we generated mice expressing a single 
allele of Jnk1 or Jnk2 in hematopoietic cells. Because the com-
plete absence of both Jnk1 and Jnk2 causes early embryonic 
lethality, we intercrossed Jnk1+/−/Jnk2+/− mice and collected 
fetal liver cells. Then, 17-week-old male Ldlr−/− mice were 
lethally irradiated and reconstituted with male WT (n=10), 
Jnk1−/− (n=10), Jnk1+/−/Jnk2−/− (n=13), and Jnk1−/−/Jnk2+/− 
(n=12) fetal liver cells. Four weeks after transplantation, these 
mice were challenged with the Western diet for 8 weeks. 
Again, there were no differences between the recipient groups 
in body weight and plasma lipid levels either on the chow 
or the Western diets (Table, B). Macrophages isolated from 
mice with a single JNK allele exhibited further decrease in 
JNK protein content compared with Jnk1−/− and WT cells 
(Figure II in the online-only Data Supplement). Remarkably, 
both Jnk1+/−/Jnk2−/−→Ldlr−/− and Jnk1−/−/Jnk2+/−→Ldlr−/− 
mice developed larger atherosclerotic lesions with increased 
macrophage MOMA-2–positive area in the proximal aorta 
(Figure 2E and 2F) than Jnk1−/−→Ldlr−/− and WT−/−→Ldlr−/− 
mice (Figure 2C, 2F, and 2G; 183% and 172% versus 131% 
and 100%, respectively). Similarly, the analysis of aorta en 
face demonstrated that these Jnk1+/−/Jnk2−/−→Ldlr−/− and 
Jnk1−/−/Jnk2+/−→Ldlr−/− mice had larger atherosclerotic lesions 
compared with Jnk1−/−→Ldlr−/− and WT−/−→Ldlr−/− mice 
(Figure 2H and 2I; 248% and 225% versus 171% and 100%). 
Thus, genetic ablation of JNK to a single allele in hematopoi-
etic cells resulted in further increases of atherosclerosis.
JNK1 Signaling Antagonizes Akt 
Activity in Macrophages
Next, we investigated the mechanism(s) responsible for the 
increased macrophage numbers in atherosclerotic lesions of 
Jnk1−/−→Ldlr−/− mice by focusing on Akt signaling, which is 
crucial for cell survival.20 In macrophages, Akt is constitutively 
activated, and inhibition of Akt signaling induces apoptosis.27,28 
In addition, a recent report demonstrated that JNK activity 
Figure 2. Genetic suppression of c-Jun 
NH2-terminal kinase (JNK) signaling to a Jnk 
single allele further increases atheroscle-
rosis. A, JNK protein contents in wild-type 
(WT), Jnk1−/−, and Jnk2−/− macrophages (n=3 
per group); proteins were isolated, and JNK 
protein contents were analyzed by Western 
blot; the ratio of JNK/β-actin is presented 
compared with WT cells (*P<0.05 by 1-way 
ANOVA analysis). B, Jnk1 or Jnk2 gene 
expression levels in peritoneal macrophages 
from mice reconstituted with WT (◼), Jnk1−/− 
(□), or Jnk2−/− (◼) fetal liver cells (FLC); 
mRNA levels were analyzed by real-time 
polymerase chain reaction. Graphs represent 
data (mean±SEM) with the same number 
(n=3) of mice per group (*P<0.05 by 1-way 
ANOVA). C–F, Detection of macrophages in 
the aortic sinus lesions of mice reconstituted 
with WT (C), Jnk1−/− (D), Jnk1+/−/Jnk2−/− (E), 
or Jnk1−/−/Jnk2+/− (F) FLC. Sections were 
stained with MOMA-2; Scale bar, 50 μm. 
G, The extent of macrophage lesion area 
in the proximal aorta of mice reconstituted 
with WT (◼), Jnk1−/− (□), Jnk1+/−/Jnk2−/− (◼), 
or Jnk1−/−/Jnk2+/− (◼) FLC (*P<0.05 by 1-way 
ANOVA, multiple comparisons vs control 
group; Tukey test). H, Atherosclerotic lesions 
in pinned out en face aorta of mice reconsti-
tuted with WT, Jnk1−/−, Jnk1+/−/Jnk2−/− or Jnk
1−/−/Jnk2+/− FLC. A pin size, 10 μm.  
I, The extent of the atherosclerotic lesion 
area in Ldlr−/− mice reconstituted with WT, 
Jnk1, or Jnk1+/−/Jnk2−/− or Jnk1−/−/Jnk2+/− 
FLC (*P<0.05 by Kruskal–Wallis 1-way 
ANOVA on ranks, Dunn method, vs control 
group; WT→Ldlr−/− mice).
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antagonizes Akt signaling in some types of cells.23 To exam-
ine whether JNK affects p-Akt in mouse macrophages, WT, 
Jnk1−/−, and Jnk2−/− peritoneal macrophages were treated with 
insulin alone or together with anisomycin, a known activator 
of JNK signaling.23 Insulin significantly (2–3-fold) activated 
phosphorylation of both Akt sites (p-AktS473 and T308) in all 
types of cells (Figure 3A), whereas anisomycin suppressed Akt 
signaling activity in WT and Jnk2−/− macrophages, respectively, 
with no changes in total Akt or β-actin content (Figure 3A). 
Importantly, Jnk1−/− macrophages showed significantly less 
effect of JNK signaling on Akt activity than WT or Jnk2−/− cells 
(Figure 3B). The analysis of p-AktS473/Akt and p-Akt T308/Akt 
ratio in the same blot indicated a similar protective effect of 
Jnk1 deficiency compared with WT or Jnk2−/− cells (Figure 3C 
and 3D). Direct comparison of WT and Jnk1−/− macrophages 
treated with insulin and anisomycin demonstrated a statistically 
significant inhibitory effect of JNK signaling in the p-Akt/β-
actin ratio of WT but not of Jnk1−/− macrophages (Figure 3E 
and 3F). Thus, JNK1 is the isoform primarily responsible for 
JNK-mediated inhibition of Akt signaling in macrophages.
We also examined whether pharmacological inhibition 
of JNK can prevent the negative effects of JNK signaling on 
p-Akt. WT peritoneal macrophages were incubated with a 
mixture of insulin and anisomycin alone or in the presence of 
a JNK inhibitor. There was a 39% reduction of p-Akt levels in 
WT cells treated with anisomycin and a cell-permeable pep-
tide inhibitor of JNK1, JNKI1, which preserved p-Akt levels 
in macrophages (Figure 4A and 4B). In contrast, treatment 
with a cell-permeable inhibitor IX, selective for JNK2 and 
JNK3 with little or no activity against JNK1, had no protective 
effects on Akt activity (Figure 4A and 4B). Taken together, 
these data indicate that genetic ablation and pharmacological 
inhibition of JNK1, but not JNK2, eliminate the suppressive 
effects of JNK signaling on Akt activity.
JNK1 Deficiency Protects 
Macrophages From Apoptosis
JNK signaling has proapoptotic or antiapoptotic functions, 
depending on the cell type, nature of the death stimulus, dura-
tion of its activation, and the activity of other signaling path-
ways.17 Taking into consideration the critical role of Akt in 
cell survival,20 we suggested that sustained JNK activation 
(1–6 hours) may promote apoptosis by exhausting antiapop-
totic Akt signaling and by subsequently reducing Bad S136 
phosphorylation, which normally serves to inhibit apoptosis 
in macrophages.27,29 To test this hypothesis, we examined 
the effect of anisomycin on Akt signaling in WT and Jnk1−/− 
macrophages treated with palmitic acid, a stress-mediated 
Figure 3. c-Jun NH2-terminal kinase (JNK) 
signaling antagonizes p-Akt activity, and 
loss of JNK1 obliterated this effect. A, Wild-
type (WT), Jnk1−/−, and Jnk2−/− peritoneal 
macrophages were preincubated in serum-
free media for 24 hours and then untreated 
or treated with insulin (100 nmol/L) alone 
or together with anisomycin (10 μg/mL) 
for 15 minutes. Macrophage proteins were 
extracted, resolved by electrophoresis (50 
μg), and analyzed by Western blot. B–D, 
Ratio of p-AktS473/b-actin, p-AktS473/
Akt, and p-Akt T308/Akt in untreated (white 
color) or treated with insulin (green color) or 
insulin plus anisomycin (blue color). Graphs 
represent data (mean±SEM) of 3 experi-
ments (*P<0.05 by 1-way ANOVA on rank 
compared with control WT cells treated with 
insulin together with anisomycin).  
E and F, WT and Jnk1−/− macrophages were 
treated with insulin alone (green color) or 
together with anisomycin (blue color) for 
10 and 15 minutes. Graphs represent data 
(mean±SEM) of 3 experiments (*P<0.05 by 
1-way ANOVA on rank compared with WT 
cells treated with insulin).
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lipotoxic factor inducing endoplasmic reticulum (ER) stress 
and apoptosis.30 The increased JNK signaling gradually sup-
pressed p-Akt S473 in WT cells, whereas Jnk1−/− macrophages 
had higher p-Akt S473 levels and were more resistant to p-Akt 
suppression (Figure 4C and 4D). Similarly, the treatment 
progressively reduced p-Bad S136 levels in WT macrophages, 
but there was less attenuation of p-Bad S136 in Jnk1−/− cells 
(Figure 4C). Thus, compared with WT cells, Jnk1−/− macro-
phages were able to preserve higher levels of Akt and Bad 
phosphorylation, which are important protective and anti-
apoptotic factors under conditions of ER stress.31
In addition, to define the role of JNK signaling in macro-
phage apoptosis, WT, Jnk1−/−, and Jnk2−/− macrophages were 
treated with bovine serum albumin or palmitic acid. Treatment 
with bovine serum albumin generated only a few apoptotic 
TUNEL-positive (TUNEL+) cells with no differences between 
cell types, whereas palmitic acid increased TUNEL+ cells 
4-fold in WT and Jnk2−/− macrophages but not in Jnk1−/− cells 
(Figure 5A and 5B). The addition of anisomycin markedly 
(3-fold) increased the percentage of TUNEL+ cells to a simi-
lar degree in WT and Jnk2−/− cells, whereas apoptosis was sig-
nificantly reduced (57% of WT cells) in Jnk1−/− macrophages 
(Figure 5C). In contrast, the selective inhibitor JNKI1 sig-
nificantly (2-fold) reduced apoptosis in all types of cells, but 
Jnk1−/− macrophages had less apoptosis than WT and Jnk2−/− 
cells (Figure 5D). When WT macrophages were treated with the 
specific inhibitors of JNK, JNKI1, and SP600125, they dem-
onstrated similar levels of apoptosis (Figure 5E). Importantly, 
when cells were loaded with human oxidized or acetylated 
LDL in combination with an ACAT (acetyl-coenzyme A acet-
yltransferase) inhibitor, Jnk1−/− macrophages generated signifi-
cantly less apoptosis than WT and Jnk2−/− cells (Figure 5F). In 
addition, macrophages expressing a single Akt isoform (Figure 
III in the online-only Data Supplement), Akt1 (Akt2−/−/Akt3−/−), 
or Akt3 (Akt1−/−/Akt2−/−) palmitic acid–bovine serum albumin 
treatment induced a stepwise increase in apoptosis that was 
especially high in Akt1−/−/Akt2−/− cells compared with WT cells. 
However, suppression of JNK signaling by the JNK inhibitor, 
SP600125, completely reversed the effect on cell survival with 
no differences between the groups (Figure IV in the online-
only Data Supplement). Taken together, our data indicate that 
JNK1 signaling regulates ER stress–mediated apoptosis in 
mouse macrophages and Jnk1−/− macrophages displayed clear 
resistance to apoptosis induced by different stimuli.
PTEN Suppression Impairs Effects of 
JNK Signaling on Akt Activity
Recently, Vivanco et al26 have shown that JNK regulates 
p-Akt via PTEN, and Pten null mouse embryonic fibroblasts 
exhibit an impaired negative feedback loop. To test whether 
PTEN plays a critical role in regulating this pathway in mouse 
macrophages, WT and Pten−/− cells were treated with insulin 
alone or together with anisomycin. In contrast to WT cells, 
which showed increased p-Akt S473 in response to insulin and 
reduced p-Akt S473 after treatment with anisomycin, Pten−/− 
macrophages had markedly increased basal p-Akt, which was 
not suppressed in response to anisomycin (Figure 6A and 6B). 
Similarly, treatment with bpV(pic), a potent PTEN inhibitor, 
with an IC
50
 ≈10- to 100-fold lower than for other tyrosine 
phosphatases,32 decreased the inhibitory effects of JNK on 
p-Akt (Figure 6C and 6D). Taken together, these results indi-
cate that both genetic ablation and pharmacological inhibition 
of PTEN effectively eradicated JNK-mediated inhibition of 
Akt phosphorylation in mouse macrophages.
Discussion
Numerous studies have linked macrophage or hematopoietic 
JNK1 activity to insulin resistance and abnormal glucose 
homeostasis in obesity.12,33–35 These studies targeting individual 
Figure 4. c-Jun NH2-terminal kinase-1 
(JNK1) inhibitor, JNKI1, preserves Akt 
signaling, and Jnk1−/− macrophages are 
more resistant to endoplasmic reticulum 
stress than wild-type (WT) cells. A and B, 
WT peritoneal macrophages were prein-
cubated in serum-free media for 24 hours 
and then treated with insulin alone (green 
color) or together with anisomycin (Ani; 
blue color) without or with the specific JNK 
inhibitor 1, JNKI1 (3 μmol/L) or specific 
JNK2 and JNK3 inhibitor, inhibitor IX (50 
nmol/L), for indicated time. Macrophage 
proteins were extracted, resolved (60 μg 
per well), and analyzed by Western blot with 
noted antibodies. Graphs represent data 
(mean±SEM) of experiments with 4 mice 
per group (*P<0.05 compared with control 
WT cells treated with insulin for 15 minutes 
by 1-way ANOVA on ranks). C and D, WT 
(◼) and Jnk1−/− (□) peritoneal macrophages 
were untreated or treated with 0.5 mmol/L 
palmitic acid–bovine serum albumin and 
Ani (10 μg/mL) for the indicated time. 
Graphs represent data (mean±SEM) of 3 
experiments.
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JNK isoforms have produced varying degrees of effect in dif-
ferent models, perhaps because of interactions between iso-
forms and redundancies.8 In fact, a recent report using Jnk1 
and Jnk2-combined deletion has shown that macrophage JNK 
promotes the establishment of obesity-induced insulin resis-
tance and pancreatic islet dysfunction.12 These findings suggest 
that macrophage JNK signaling may be crucial in other patho-
logical conditions and warrants detailed studies of individual 
isoforms in cardiovascular disease models. Here, we examined 
the effect of Jnk1 or Jnk2 deficiency in hematopoietic cells 
on early stages of atherosclerosis using the Ldlr-deficiency 
model. Mice reconstituted with Jnk1−/− hematopoietic cells 
had significantly bigger atherosclerotic lesions compared with 
mice transplanted with WT or Jnk2−/− marrow with no differ-
ences in serum lipids. Genetic ablation to a single Jnk allele 
(either Jnk1+/−/Jnk2−/− or Jnk1−/−/Jnk2+/−) in hematopoietic 
cells further increased atherosclerosis compared with Jnk1−/−
→Ldlr−/− mice. We also found that JNK signaling antagonizes 
Akt activity in mouse macrophages acting mainly through 
JNK1. Therefore, Jnk1−/− macrophages had less suppression 
of p-Akt in response to sustained ER stress and were protected 
from apoptosis. On the basis of these data, we conclude that 
this resistance to apoptotic stimuli in Jnk1 null macrophages 
increases lesion burden at the early stages of atherogenesis.
JNK signaling is overexpressed and activated in atheroscle-
rotic lesions of cholesterol-fed rabbits.36 Considering the role 
of JNK in inflammatory and metabolic responses, it is plau-
sible that this stress-mediated JNK activation may affect mac-
rophage viability and atherosclerosis. In fact, Ricci et al16 were 
the first to report the involvement of JNK2 in atherosclerosis 
showing that Jnk2−/−/apoE−/− mice developed less atheroscle-
rosis compared with control apoE−/− and Jnk1−/−/apoE−/− mice. 
They analyzed a later stage of atherosclerosis with more 
severe lesions induced by a high cholesterol (1.25%) diet for 
Figure 5. Jnk1−/− macrophages are protected from apoptosis and anisomycin (Ani) increases, whereas JNK inhibition suppresses endo-
plasmic reticulum–mediated apoptosis. A, Detection of apoptosis in wild-type (WT), Jnk1−/−, and Jnk2−/− macrophages treated with bovine 
serum albumin (BSA; control) and 0.5 mmol/L palmitic acid (PA)–BSA for 24 hours by terminal deoxynucleotidyl transferase-mediated dUTP 
nick-end labeling (TUNEL) assay. Note: TUNEL-positive cells (red), nuclei counterstained with Mayer hematoxylin. B, Percent of TUNEL+ 
WT, Jnk1−/−, and Jnk2−/− macrophages treated with BSA or PA-BSA (*P<0.05 by 1-way ANOVA on rank compared with WT cells treated 
with PA-BSA). C and D, Percent of TUNEL+ WT, Jnk1−/−, and Jnk2−/− macrophages treated with BSA or PA-BSA together with Ani (10 mg/
mL) or the JNK inhibitor, JNKI1 (3 μmol/L), for 24 hours (*P<0.05 by 1-way ANOVA on rank compared with WT cells treated with PA+Ani or 
PA+SP600125 [SP]). E, Percent of TUNEL+ cells in WT macrophages untreated or treated with 0.5 mmol/L PA-BSA alone or together with 
JNK inhibitors, SP (100 nmol/L) or JNKI1 (3 μmol/L) for 24 hours (*P<0.05 by 1-way ANOVA on rank compared with untreated WT cells). F, 
Percent of TUNEL+ in WT, Jnk1−/−, and Jnk2−/− macrophages untreated (control) or treated with human acetylated low-density lipoprotein 
(AcLDL; 100 μg/mL) in the presence of the ACAT (acetyl-coenzyme A acetyltransferase) inhibitor CP-113,818 (2 μg/mL) or human oxidized 
LDL (OxLDL; 100 μg/mL) for 48 hours (*P<0.05 compared with control WT cells treated with AcLDL by 1-way ANOVA on rank).
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14 weeks in total body JNK isoform deficiency in the apoE-
deficienct model on a hybrid C57BL6/129SV background, 
whereas in the current study, we explored early-stage athero-
sclerosis using Ldlr−/− mice on C57BL/6 background recon-
stituted with hematopoietic cells null for JNK isoforms and 
fed with the Western diet (containing 21% milk fat and 0.15% 
cholesterol) for 8 weeks. The variation in genetic background 
of mice, stage-specific lesion burden, and Jnk deficiency in 
specific compartments are all important determinants of cho-
lesterol absorption37 and susceptibility to atherosclerosis,38 and 
they may underlie the apparent differences in our results.
In the current study, we observed a higher lesion burden 
in early atherosclerosis as a result of deficiency of Jnk1, but 
not Jnk2, in hematopoietic cells in the Ldlr null mice. Similar 
results were also obtained when combined deletion models 
(either Jnk1+/−/Jnk2−/− or Jnk1−/−/Jnk2+/−) were used as donors 
to produce hematopoietic JNK deficiency. These results may 
point to several possibilities. For example, it is possible that 
total JNK activity may be a more important determinant of the 
effect on macrophage apoptosis and atherogenesis than separate 
JNK isoforms. In the future, it would be highly informative to 
examine interactions between JNK isoforms in supporting total 
JNK activity in vivo. In this sense, our data are consistent with 
a recent report,39 indicating that loss of apoptosis signal-regu-
lating kinase 1, which is upstream of JNK in certain contexts, 
in apoE null mice significantly reduced apoptosis and increased 
atherosclerosis by forming lesions enriched with macrophages. 
Because of the complexity of signaling upstream of JNK, mul-
tiple mechanisms may affect atherogenesis in a differential 
manner. For example, lack of mitogen-activated protein kinase 
phosphotase-1 protects apoE null mice from atherosclerosis,40 
whereas genetic deletion of Jnk1 reduces apoptosis in endothe-
lial cells at atheroprone sites of the artery and thus diminishes 
atherosclerosis.41 Similarly, the administration of anisomycin 
via osmotic minipump increased apoptosis and decreased the 
macrophage content in atherosclerotic lesions of rabbits.42 In 
this scenario, prevention of macrophage death is likely a domi-
nant feature of Jnk deficiency, at least during early stages of 
atherosclerosis, supporting the growth of vascular lesions 
enriched in macrophages. If this is the case, careful consider-
ation of JNK’s role in atherosclerosis and how it could be best 
used for therapeutic intervention would be well warranted. It 
is, however, equally likely that Jnk1 deficiency and early pres-
ervation of macrophage death may yield favorable functional 
outcomes by ensuring plaque stability and preventing rupture, 
the predominant cause of morbidity and mortality caused by 
atherosclerosis.43 In fact, this would be quite reminiscent of the 
role of certain ER stress responses that are also related to mac-
rophage death.2 For example, C/EBP homologous protein defi-
ciency can prevent macrophage death and support the stability 
of vascular lesions and prevent rupture.44 Finally, it is possible 
that isolated examination of hematopoietic JNK activity only 
may have limitations and may not reflect the complete role 
of JNK in the pathogenesis of atherosclerosis. Future studies 
should dissect these possibilities in additional models.
Next, to identify the mechanism(s) responsible for the 
actions of JNK signaling in macrophages, we focused on the fact 
that Jnk1−/−→Ldlr−/− mice had a dramatic decrease in apoptosis 
and increased numbers of macrophages in their atherosclerotic 
lesions compared with lesions of WT→Ldlr−/− and Jnk2−/−→L
dlr−/− mice. These results suggested that Jnk1 deficiency changes 
the balance between survival and proapoptotic signaling in mac-
rophages at least in the setting they are examined. Indeed, our in 
vitro studies demonstrated that JNK signaling directly antago-
nizes Akt activity in mouse macrophages. This effect occurs 
within a short time (3–15 minutes) and may be beneficial for 
Figure 6. Genetic and pharmacological inhi-
bition of phosphatase and tensin homolog 
(PTEN) eradicates anisomycin-mediated 
suppression of p-Akt in macrophages.  
A and B, Akt signaling in wild-type (WT) and 
Pten−/− macrophages treated with insulin 
and anisomycin. Cells were preincubated 
with serum-free media for 16 hours and 
then untreated or treated with insulin alone 
(green color) or together with anisomycin 
(blue color) for the indicated time. Graphs 
represent data (mean±SEM) of 3 experi-
ments (*P<0.05 between untreated and 
treated cells by 1-way ANOVA). C and D, 
PTEN inhibitor bpV(pig) preserves p-Akt 
signaling in WT peritoneal macrophages 
treated with anisomycin. Cells were preincu-
bated in serum-free media for 24 hours and 
treated with insulin alone (green color) or 
with anisomycin (blue color) with or without 
bpV(pig) (0.1 μmol/L) for 15 minutes. Graphs 
represent data (mean±SEM) of 2 experi-
ments (*P<0.05 by 1-way ANOVA on rank 
compared with cells treated with insulin).
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inflammatory and stress responses by diverting energy sources 
from the synthetic Akt pathway.3 In contrast, prolonged or sus-
tained JNK activation suppresses Akt signaling and induces 
cell apoptosis.6 Interestingly, this antagonizing effect is medi-
ated mainly through JNK1, but not JNK2, and genetic ablation 
or pharmacological inhibition of JNK1 completely obliterated 
this effect. These data are consistent with the previous reports, 
indicating that JNK signaling acts as a negative feedback loop 
that attenuates insulin action and insulin-induced PI3K activa-
tion.7,12,23,45–47 Together, our data indicate that JNK1 signaling 
antagonizes and suppresses Akt activity in mouse macrophages.
It is important to note that bone marrow transplantation 
may change every component of hematopoietic system in 
mice, including monocyte-macrophages, T and B cells, and 
platelets. Several studies have shown that JNK is required for 
effector T-cell function.48 JNK2 is important for T-cell activa-
tion and apoptosis of immature thymocytes49 and plays a role 
in control of CD8+ T-cell expansion in vivo, whereas JNK1 
is involved in survival of activated T cells during immune 
responses.50 Moreover, JNK1 is essential for platelet secretion 
and thrombus formation.51 Therefore, we cannot exclude that 
these changes may also affect atherogenesis.
It is known that sustained JNK signaling restrains Akt 
activity, the major prosurvival signaling pathway that opposes 
apoptosis,20 suggesting a potential mechanism for impaired 
macrophage viability. In our experiments, sustained JNK sig-
naling under conditions of ER stress gradually extinguished 
Akt and Bad (S136) activity in WT cells, whereas Jnk1−/− macro-
phages were much less affected (Figure 4C and 4D). Compared 
with WT cells, Jnk1−/− macrophages were also protected from 
apoptosis initiated by different stimuli. Moreover, JNK1 inhi-
bition distinctly decreased ER stress–mediated apoptosis in 
macrophages. These results are consistent with the concept that 
chronically activated JNK1 signaling is crucial in type 2 diabe-
tes mellitus and obesity.8,11,47,52 JNK-mediated phosphorylation 
of insulin receptor substrates 1 and 2 disrupts Akt signaling33,46 
possibly by releasing Bad for translocation to the mitochondria23 
or association with Bcl-2/Bcl-xL and initiation of apoptosis. 
In addition, we examined whether macrophages use a natural 
brake of Akt signaling, PTEN, to suppress p-Akt. Given that 
PTEN has been reported to cooperate with JNK53 to couple the 
PI3K/Akt and JNK signaling pathways,26 we examined whether 
PTEN mediates cross talk between these pathways in mouse 
macrophages. Our results demonstrate that genetic and phar-
macological inhibition of PTEN virtually eradicates the JNK-
mediated effect on p-Akt in macrophages. Thus, JNK signaling 
may also act via PTEN to antagonize Akt activity and suppress 
macrophage survival. Macrophage-derived foam cells are the 
predominant cell type of early atherosclerotic lesions, and loss 
of macrophages through increased apoptosis may reduce the 
size of early atherosclerotic lesions.54 Together, these data dem-
onstrate that Jnk1 deficiency significantly increases macrophage 
survival, and this leads to cell accumulation in early-stage ath-
erosclerotic lesions. Importantly, JNK and PTEN signaling in 
macrophages can be altered pharmacologically with the use of 
their ligands or inhibitors, supporting these pathways as new 
potential therapeutic targets for the prevention of atherosclerosis 
and allowing for functional studies in a stage-specific manner.
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•	 c-Jun NH2-terminal kinase-1 (JNK1) signaling antagonizes prosurvival Akt activity in mouse macrophages.
•	 Jnk1 null macrophages were less affected by the stress factors and more protected from apoptosis than wild-type and Jnk2 null macrophages.
•	 Loss of Jnk1, but not Jnk2, in hematopoietic cells significantly increases early atherosclerosis.
•	 Genetic ablation of JNK to a single allele (Jnk1+/−/Jnk2−/− or Jnk1−/−/Jnk2+/−) in bone marrow recipients further increased atherosclerosis 
compared with mice reconstituted with wild-type or Jnk1 null bone marrow.
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Figure SII. Dose-dependent suppression of JNK protein contents in wild type, 
Jnk1-/- and single Jnk allele macrophages.  
A,B. JNK protein contents in WT, Jnk1-/- , Jnk1+/-/Jnk2-/- and Jnk1-/-/Jnk2+/- 
macrophages  and the ratio of JNK/b-actin is presented  compared to WT cells.  
Macrophage proteins were extracted, resolved (40μg/well) and analyzed by 
Western blot.  
Figure SI. c-Jun  kinase assay in WT, Jnk1-/- and Jnk2-/- macrophages treated 
with thapsigargin. 
Peritoneal macrophages from WT, Jnk1-/-(1) and Jnk2-/-(2) mice were isolated  and 
two days later, untreated or treated with 1mM thapsigargin (TPG) for 6 hours. Then 
proteins were extracted, resolved (50μg/well) and analyzed by Western blot.  
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Figure SIII. Akt isoform expression in Akt2/3 and Akt1/2 knockout macrophages  
Peritoneal macrophages were isolated  from mice reconstituted with WT, Akt2/3KO and 
Akt1/2KO FLC (n = 3/group). Proteins were extracted from macrophages, resolved   
(50μg/well) and analyzed by Western blot using an Akt isoform sampler kit.  
Figure SIV. Macrophages with a single Akt1 or Akt3 isoform are more sensitive to ER 
stress and apoptosis but the JNK inhibition eliminates the increase in apoptosis. 
A. WT, Akt2/3KO  and Akt1/2KO macrophages were treated with BSA, the JNK inhibitors, 
SP600125 (SP, 100nM), 0.5mM PA-BSA (PA) and mixture of PA plus SP for 24 hours. 
Apoptotic cells were detected by the Alexa Flour 488 Annexin V/Dead cell apoptosis kit. Note 
the Annexin revealed apoptotic cells (green), propidium iodide detected dead cells (red) and 
DAPI stained nuclei (blue).  
B Percent of apoptotic cells in WT, Akt2/3KO  and Akt1/2KO macrophages treated with BSA, 
SP, PA or PA plus SP (*p<0.05 by One Way Analysis of Variance on Rank compared to WT 
cells treated with PA). 
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Material and Methods 
 
Animal Procedures: Mice deficient for Jnk1 and Jnk2 were on the C57BL/6 
background (10th backcross), recipient Ldlr-/- (on C57BL/6 background) and C57BL/6 
mice were purchased from the Jackson Laboratories (Bar Harbor, ME). Mice were 
maintained in microisolator cages on a rodent chow diet containing 4.5% fat (PMI 
5010, St. Louis, MO) or a Western type diet containing 21% milk fat and 0.15% 
cholesterol Teklad, Madison, WI). Animal care and experimental procedures were 
performed according to the regulations of Vanderbilt University's Animal Care 
Committee.  
Bone Marrow Transplantation and Serum Lipid Analyses: Recipient mice were 
lethally irradiated (9Gy) from a cesium gamma source and transplanted with 5x106 
bone marrow cells as described 1. FLC were collected as described 2. The serum 
total cholesterol and triglyceride levels were determined on 24-hour fasting samples 
using enzymatic assays (Roche) as described 3. Fast performance liquid 
chromatography (FPLC) was performed on an HPLC system model 600 (Waters, 
Milford, MA) using a Superose 6 column (Pharmacia, Piscataway, NJ).  
Analysis of Aortic Lesions: Aortas were flushed through the left ventricle and the 
entire aorta was dissected for en face analysis as described 4. Cryosections of the 
proximal aorta (n=15/sinus) were analyzed using an Imaging system KS 300 
(Kontron Electronik GmbH.) 2.  
Immunocytochemistry: Serial 5-micron cryosections of the proximal aorta were fixed 
with acetone and stained with the appropriate antibodies including rat antibody to 
macrophages, MOMA-2 or CD68 (Accurate Chemical & Scientific Corp., Westbury, 
NY), rat anti-mouse T-cells, CD90.2 (Thy 1.2 from BioLegend),  rat anti-CD3 antibody 
(17A2 from BD Biosciences), and mouse antibody to smooth muscle cells (1A4 from 
Sigma). A non-immune rat and mouse sera were used as a negative control. Double 
staining of macrophages with MOMA-2 and cell nuclei with DAPI with analysis of 
nucleus numbers in macrophage area as previously described 5. 
Peritoneal macrophage isolation and treatment. Thioglycollate-elicited peritoneal 
macrophages were isolated as described from WT, Jnk1-/- and Jnk2-/- mice 
reconstituted with wild type, bone marrow. Then macrophages were treated with 
bovine pancreatic insulin  alone or with anisomycin (both from Sigma-Aldrich), 
palmitic acid complexed to BSA prepared as described 6,  the JNK inhibitors, JNKI1, 
IX, and SP600125, and the PTEN inhibitor, bpV(pic) (all from EMD Millipore); AcLDL 
and oxLDL (from Intracel, Inc) and ACAT inhibitor, CP-113,818 (Sigma).  
RNA Isolation and real-time PCR. Total RNA was isolated from peritoneal 
macrophages using the Trizol reagent (Life Technologies, Inc.) and purified by RNA 
Easy kit (Qiagen, Valencia, CA). Relative quantitation of the target mRNA was 
performed using the ABI Prism 7700 Sequence Detection System (Applied 
Biosystems, ABI) and normalized with 18S ribosomal RNA as an endogenous 
control. 
Apoptosis assessment. Peritoneal macrophages were cultured in Laboratory-Tek 
chamber slides (Nalge Nunc International). Cryosections of 5-micron were obtained 
from the proximal aorta. Cultured cells and sections were fixed in 2% 
paraformaldehyde, and apoptotic cells were detected by the Alexa Flour 488 
 2 
Annexin V/Dead cell apoptosis kit (Life Technologies) and by the TUNEL (TdT-
mediated dUTP nick end labeling) technique using the in situ cell death detection kit 
(Roche Applied Science). TUNEL-positive (TUNEL+) cells were counted in 6 
different sections from each aorta. 
Macrophage-specific Pten knockout mice. Using the Cre-loxP recombination 
system, we generated  mice with Pten knockout in myeloid cells. Mice with loxP 
sites flanking exon 5 of the Pten gene (from the Jackson laboratory, stock number 
006440) were crossed with a mouse Cre line under the control of the murine M 
lysozyme promoter 7 on the C57BL/6 background (nine backcross into C57BL6) 
similarly as described 5. These mice were viable and fertile with no notable 
differences in body weight or plasma lipid levels when compared with control 
C57BL6 mice.  
Western blotting. Cells were lysed on ice with a lysis buffer (Cell Signaling 
Technology, Danvers, MA) containing a protease (Sigma) and phosphatase 
(Pierce) inhibitor cocktail. Protein concentrations were determined with the DC 
Protein assay kit (Bio-Rad Laboratories). Lysates (20 or 100 µg/lane) were 
resolved by NuPAGE Bis-Tris elecrophoresis (Invitrogen) and transferred onto 
polyvinylidene difluoride nitrocellulose membranes (Amersham Bioscience). Blots 
were probed with rabbit antibodies to Akt, p-Akt S473, p-Akt T308, p-Bad S136, p-JNK 
and PTEN (all from Cell signaling), β-actin antibody (Abcam, Inc. Cambridge, MA) 
and goat anti-rabbit horseradish peroxidase-conjugated secondary antibodies 
(Sigma). Proteins were visualized with ECL western blotting detection reagents 
(GE healthcare) on X-ray films. Protein levels were quantified by densitometry 
normalizing to -actin. 
Statistical Analyses:  Data are provided as means ± SEM. Multiple groups were 
compared by One-way ANOVA or non-parametric Kruskal-Wallis test using a 
SPSS Statistics Premium 22 (IBM, Armonk, NY:IBM Corp). These tests initially 
measure normality to choose parametric or nonparametric analysis (the details 
are presented in each figure legend). A difference was considered to be 
statistically significant at a P-value less than 0.05. 
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